William M. Wells has resigned as Chairman of the Board of Valeant Pharmaceuticals and has been replaced by Robert A. Ingram. Valeant subsidiary Biovail is co-devloping the Staccato loxapine inhaler with Alexza Pharmaceuticals. The FDA issued a complete response letter for Staccato loxapine in October 2010. The announcement comes less than two weeks after Elan announced that Robert A. Ingram would chair its board. Read the Elan press release. Read the Valeant press release.
Robert A. Ingram appointed Chairman of Valeant Board
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
